Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBITDA Margin (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed EBITDA Margin for 16 consecutive years, with 70.0% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 5108.0% to 70.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.44% through Dec 2025, down 4942.0% year-over-year, with the annual reading at 69.44% for FY2025, 4942.0% down from the prior year.
  • EBITDA Margin hit 70.0% in Q4 2025 for Vanda Pharmaceuticals, down from 55.07% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 18.72% in Q2 2021 to a low of 81.53% in Q1 2025.
  • Historically, EBITDA Margin has averaged 15.81% across 5 years, with a median of 13.57% in 2022.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 1666bps in 2021 and later crashed -6250bps in 2025.
  • Year by year, EBITDA Margin stood at 13.19% in 2021, then dropped by -19bps to 10.69% in 2022, then crashed by -243bps to 15.26% in 2023, then decreased by -24bps to 18.91% in 2024, then plummeted by -270bps to 70.0% in 2025.
  • Business Quant data shows EBITDA Margin for VNDA at 70.0% in Q4 2025, 55.07% in Q3 2025, and 72.71% in Q2 2025.